Literature DB >> 6977944

Characterization of various immunoglobulin preparations for intravenous application. I. Protein composition and antibody content.

J Römer, J J Morgenthaler, R Scherz, F Skvaril.   

Abstract

In this comparative study we investigated 14 immunoglobulin (Ig) preparations for intravenous application; they were prepared by various manufacturers who used either placental or venous blood as the starting material. The pepsin- and plasmin-treated products and a preparation which, according to the manufacturer, was not degraded enzymatically, contained 17-86% of IgG split products. On the other hand, three chemically modified preparations, one preparation treated at pH 4, for products treated with poly(ethylene glycol) (PEG) and one preparation protected by albumin contained 90% or more of non-fragmented IgG. The IgG subclass distribution corresponded to the distribution of subclasses in normal serum only in the nonmodified and not enzymatically degraded preparations. All samples except one contained 0.1 mg/ml IgA or more, all contained only traces of IgM. No product had clinically relevant titers of irregular antibodies against erythrocyte antigens. The content of those antiviral and antibacterial antibodies that were tested for was similar in all preparations. Only the anti-HBs activity exhibited large variations. Some PEG-treated preparations showed an elevated prekallikrein activator (PKA) level, whereas all other preparations contained, if any, only traces of PKA.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6977944     DOI: 10.1159/000460850

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  27 in total

1.  A comparative study of the in vitro immunomodulatory activity of human intact immunoglobulin (7S IVIG), F(ab')2 fragments (5S IVIG) and Fc fragments. Evidence for post-transcriptional IL-2 modulation.

Authors:  D Nachbaur; M Herold; B Eibl; H Glassl; H Schwaighofer; C Huber; A Gächter; M Pichl; D Niederwieser
Journal:  Immunology       Date:  1997-02       Impact factor: 7.397

Review 2.  New and old aspects of immunoglobulin application. The use of intravenous IgG as prophylaxis and for treatment of infections.

Authors:  L Hammarström; C I Smith
Journal:  Infection       Date:  1990 Sep-Oct       Impact factor: 3.553

3.  Neutrophil bactericidal activity against Staphylococcus aureus adherent on biological surfaces. Surface-bound extracellular matrix proteins activate intracellular killing by oxygen-dependent and -independent mechanisms.

Authors:  M Hermann; M E Jaconi; C Dahlgren; F A Waldvogel; O Stendahl; D P Lew
Journal:  J Clin Invest       Date:  1990-09       Impact factor: 14.808

4.  Multicenter crossover comparison of the safety and efficacy of Intraglobin-F with Gamimune-N, Sandoglobulin, and Gammagard in patients with primary immunodeficiency diseases.

Authors:  R I Schiff; L W Williams; R P Nelson; R H Buckley; W Burks; R A Good
Journal:  J Clin Immunol       Date:  1997-01       Impact factor: 8.317

5.  9 Human Immunoglobulins.

Authors: 
Journal:  Transfus Med Hemother       Date:  2009       Impact factor: 3.747

Review 6.  Mechanism of action of intravenous immunoglobulin in immune-mediated cytopenias.

Authors:  H I Atrah; R J Davidson
Journal:  J Clin Pathol       Date:  1988-12       Impact factor: 3.411

7.  Characterization of the subclasses and light chain types of IgG antibodies to rubella.

Authors:  F Skvaril; U Schilt
Journal:  Clin Exp Immunol       Date:  1984-03       Impact factor: 4.330

Review 8.  Intravenous immune globulin in primary immunodeficiency.

Authors:  M Haeney
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

9.  Efficacy of intravenous immunoglobulin preparations against viral and bacterial infections in mouse protection tests.

Authors:  W Stephan; H Dichtelmüller
Journal:  Infection       Date:  1983 Jul-Aug       Impact factor: 3.553

10.  Immune thrombocytopenia and Fc receptor-mediated phagocyte function.

Authors:  A C Newland; M G Macey
Journal:  Ann Hematol       Date:  1994-08       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.